Critical Reviews in Oncology / Hematology Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis Roberto Petrioli, Giandomenico Roviello, Laura Zanotti, Franco Roviello, Karol Polom, Alberto Bottini, Luigi Marano, Edoardo Francini, Daniele Marrelli, Daniele Generali Critical Reviews in Oncology / Hematology Volume 102, Pages 82-88 (June 2016) DOI: 10.1016/j.critrevonc.2016.04.001 Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions
Fig. 1 Trial selection flow chart. Critical Reviews in Oncology / Hematology 2016 102, 82-88DOI: (10.1016/j.critrevonc.2016.04.001) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions
Fig. 2 Forest plots of the risk ratio (RR) for the objective response comparing EPI-based chemotherapy with D-based chemotherapy in metastatic gastric cancer. Chi-squared test showed low heterogeneity between the trials. The fixed-effects model was used. Critical Reviews in Oncology / Hematology 2016 102, 82-88DOI: (10.1016/j.critrevonc.2016.04.001) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions
Fig. 3 Forest plots of the risk ratio (RR) for the disease control rate comparing EPI-based chemotherapy with D-based chemotherapy in metastatic gastric cancer. Chi-squared test showed low heterogeneity between the trials. The fixed-effects model was used. Critical Reviews in Oncology / Hematology 2016 102, 82-88DOI: (10.1016/j.critrevonc.2016.04.001) Copyright © 2016 Elsevier Ireland Ltd Terms and Conditions